AngioDynamics (NASDAQ:ANGO) announced its earnings results on Friday. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.01, MarketWatch Earnings reports. The business had revenue of $91.50 million for the quarter, compared to the consensus estimate of $89.24 million. AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. AngioDynamics’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period last year, the firm posted $0.16 earnings per share. AngioDynamics updated its FY 2019 guidance to $0.82-0.86 EPS and its FY19 guidance to $0.82-0.86 EPS.
Shares of NASDAQ ANGO opened at $21.52 on Friday. AngioDynamics has a one year low of $15.26 and a one year high of $24.49. The company has a current ratio of 2.64, a quick ratio of 1.55 and a debt-to-equity ratio of 0.16. The company has a market cap of $747.26 million, a price-to-earnings ratio of 29.08 and a beta of 0.74.
ANGO has been the topic of a number of recent analyst reports. BidaskClub raised shares of AngioDynamics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 8th. Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 11th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $18.44.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.